Novo Slashes Wegovy Prices Amid Lilly's Mounjaro Surge in South African Market

The Danish drugmaker launched Wegovy in South Africa in August, when ​reference pricing was uncertain due to talks with the U.S. administration on its proposed "most-favoured nation" policy linking ​U.S. drug prices to those in peer countries.

"We were of the view that the prices at the time were not conducive for the South African market," Thabeng Leping, ​who oversees market access and public affairs for Novo ⁠Nordisk South Africa, ‌told Reuters on the sidelines of an event about obesity.

"Because ​we couldn't delay ​the launch, we just decided we'll fix it as we go ⁠along," he said. "So we reduced our prices in December. We've ​submitted another reduction of our prices yesterday."

The lowest injected dose of ​Wegovy has dropped from 3,090 rand ($183) to 1,873 rand, while the highest dose has fallen 27% to 3,746 rand. A further 12% cut to the 1.7 mg dose - the second highest - is awaiting approval, Leping said.

Eli Lilly's rival Mounjaro starts at about 3,600 rand. Its share of the South African market grew to 52% at the ‌end of January, Aspen Pharmacare, the official seller of Mounjaro, said this month, predicting more than 1.3 billion rand ($77 million) in sales in ​the year through ​June.

Novo declined to give ⁠local sales figures, saying only that its products were doing "extremely well".

Speaking on a panel at the event, Novo South Africa General Manager Sara Norcross said the company intends to ​introduce its Wegovy pill locally "as soon as possible".

Both Novo and Lilly face competition from unauthorised copycat versions of their drugs, which Norcross said were used by one in two people on weight-loss treatments in South Africa despite adverse outcomes.

Novo has pursued legal action against a local compounder, while the health regulator is moving to classify such products as "undesirable."